![](https://nextgenmurr.missouri.edu/wp-content/uploads/2024/09/1000009976-1-300x200.jpg)
University of Missouri Research Reactor (MURR) wins Hawthorn Foundation Project of the Year Award
This recognition underscores Mizzou’s pivotal role in positioning Missouri as a leader in nuclear science and technology. Sept. 5, 2024 — The University of Missouri Research Reactor (MURR) has been named the 2024 Hawthorn Foundation Project of the Year Award for its groundbreaking work and significant contributions to scientific research, innovation and economic development in…
![](https://nextgenmurr.missouri.edu/wp-content/uploads/2024/06/w660_1029520_060428hoehnfeature-300x169.jpg)
Michael Hoehn II named inaugural NextGen MURR program director
June 4, 2024 — The University of Missouri has selected Michael Hoehn II as the inaugural program director for NextGen MURR.
![](https://nextgenmurr.missouri.edu/wp-content/uploads/2024/04/032624ABK-300x169.jpg)
Innovative yttrium-90 transforms liver cancer treatment
March 28, 2024 — Liver cancer is one of the deadliest forms of the disease, with an estimated 71 percent mortality rate for patients in the U.S. diagnosed with primary liver and intrahepatic bile duct cancer.
![](https://nextgenmurr.missouri.edu/wp-content/uploads/2024/02/20240130_MITC-Carolyn-Anderson-SEO-0352-300x200.jpg)
Adding a radioisotope to the toolkit for saving lives
Feb. 27, 2024 — Ground-breaking innovation provides patients around the world with access to a lifesaving toolbox of vital pharmaceutical ingredients called radioisotopes produced at MURR.
![](https://nextgenmurr.missouri.edu/wp-content/uploads/2023/12/121323Pluvicto-300x169.jpg)
MU Health Care pilots treatment for prostate cancer
Dec. 13, 2023 — University of Missouri Health Care has initiated its first treatment using an FDA-approved targeted radioactive medicine for advanced metastatic prostate cancer.
![](https://nextgenmurr.missouri.edu/wp-content/uploads/2023/12/120623MURRShipping1-300x169.jpg)
MURR ships radioisotope for cancer treatment
Dec. 6, 2023 — The University of Missouri Research Reactor (MURR) recently completed its first commercial shipment of no-carrier-added lutetium-177 for human use and is providing weekly deliveries to Novartis for use in cancer treatments.
![](https://nextgenmurr.missouri.edu/wp-content/uploads/2023/10/20231002_SE_MURR-West-Groundbreaking_ANL-041-2000x1333-1-300x200.jpg)
MU breaks ground on MURR addition
Oct. 2, 2023 — The University of Missouri hosted a groundbreaking ceremony today for a 47,000-square-foot addition to the MU Research Reactor (MURR) facility.
![](https://nextgenmurr.missouri.edu/wp-content/uploads/2023/06/Drone-Stills_42-300x169.jpg)
Matt Sanford named executive director for MURR
July 13, 2023 — University of Missouri President Mun Choi has announced Matt Sanford as executive director for the University of Missouri’s Research Reactor (MURR).
![](https://nextgenmurr.missouri.edu/wp-content/uploads/2023/07/20230413_MURR_CJH-735-300x200.jpg)
MURR continues to bolster domestic supply chain of radioisotopes
July 13, 2023 — Continuing as an essential leader in domestic isotope production, MURR began production of iron-59 (Fe-59) and manganese-54 (Mn-54) radioisotopes.
![](https://nextgenmurr.missouri.edu/wp-content/uploads/2023/06/20230314_MURR_Reactor_ANL-007-Feature-300x169.jpg)
MURR announces FDA submission for new radioisotope process
June 23, 2023 — MURR has reached a significant milestone on its path to production of no-carrier-added lutetium-177 (NCA Lu-177), a highly pure radionuclide.